德国拜耳利伐沙班治疗效果好吗

Bayer, headquartered in Leverkusen, Germany, has 750 production plants in 200 locations on six continents; it has 120,000 employees and 350 branches in almost every country in the world. Polymers, medicine and health care, chemical industry and agriculture are the company's four pillar industries. The company's product categories exceed 10,000 types. The company has produced aspirin, heroin and other products. So is the treatment produced by Bayer in Germany effective?

Rivaroxaban was approved for marketing in Canada and the European Union on September 15 and October 1, 2008 respectively. On July 1, 2011, the FDA approved the drug for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery. It was approved for marketing by the State Food and Drug Administration in March 2009, and was successfully included in the 2009 National Medical Insurance Catalog in the same year.

Rivaroxaban is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Rivaroxaban does not inhibit thrombin and has no proven effect on platelets. A dose-dependent inhibition of factor xa activity by rivaroxaban has been observed in humans.

A dose-dependent inhibition of factor Xa activity by rivaroxaban has been observed in humans. The effect of rivaroxaban on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents. Reading the PT should be completed within seconds because the International Normalized Ratio (INR) is calibrated and validated only for coumarins and not for other anticoagulants. In patients undergoing major orthopedic surgery, 5/95th (percentile) PT was (NeopLastin) 13-25 seconds 2-4 hours after taking the tablet (when the effect is strongest) (baseline value before surgery was 12-15 seconds).

Activated partial thromboplastin time (aPTT) and HepTest prolongation are also dose-dependent; however, their use in assessing the efficacy of rivaroxaban is not recommended. Rivaroxaban also has an effect on anti-factor Xa activity; however, there are currently no standards for calibration.

At the same time, the good efficacy of rivaroxaban is mainly because rivaroxaban is a highly selective oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets. A dose-dependent inhibition of factor Xa activity by rivaroxaban has been observed in humans. Clinical studies have shown that it can effectively prevent deep vein thrombosis after hip fracture surgery, has good safety, and is worthy of clinical promotion.

Recommended related hot articles: /newsDetail/90169.html